Acasti Pharma Inc
XTSX:ACST
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Acasti Pharma Inc
XTSX:ACST
|
CA |
|
Beijing Sojo Electric Co Ltd
SZSE:300444
|
CN |
|
C
|
CNPC Capital Co Ltd
SZSE:000617
|
CN |
|
Incap Oyj
LSE:0ERY
|
FI |
|
GBM Resources Ltd
ASX:GBZ
|
AU |
|
H
|
Hangzhou Robam Appliances Co Ltd
SZSE:002508
|
CN |
|
B
|
ByggPartner Gruppen AB (publ)
STO:BYGGP
|
SE |
|
Boadicea Resources Ltd
ASX:BOA
|
AU |
|
R
|
Rizzo Group AB
STO:RIZZO B
|
SE |
|
New China Life Insurance Company Ltd
SSE:601336
|
CN |
|
N
|
Namib Minerals
NASDAQ:NAMM
|
KY |
|
Shenzhen Jame Technology Corp Ltd
SZSE:300868
|
CN |
|
H
|
Huaxi Securities Co Ltd
SZSE:002926
|
CN |
|
Unggul Indah Cahaya Tbk PT
IDX:UNIC
|
ID |
|
IRadimed Corp
NASDAQ:IRMD
|
US |
|
Harmony Biosciences Holdings Inc
NASDAQ:HRMY
|
US |
|
IOI Corporation Bhd
KLSE:IOICORP
|
MY |
|
T
|
TLI Inc
KOSDAQ:062860
|
KR |
|
Sanjiang Shopping Club Co Ltd
SSE:601116
|
CN |
|
S
|
Sakana SA
WSE:SKN
|
PL |
|
Smith & Nephew PLC
NYSE:SNN
|
UK |
|
Br. Holdings Corp
TSE:1726
|
JP |
|
X
|
Xiamen International Port Co Ltd
HKEX:3378
|
CN |
Acasti Pharma Inc
Acasti Pharma, Inc. is a biopharmaceutical company, which engages in the development and commercialization of pharmaceutical applications of its licensed rights for cardiovascular diseases. The firm is targeting three underserved orphan diseases: Subarachnoid Hemorrhage (SAH), Ataxia Telangiectasia (A-T), and Postherpetic Neuralgia (PHN). The firm's lead product candidate includes GTX-104, which is a clinical-stage nanoparticle formulation of nimodipine being developed for IV infusion in SAH patients. The firm's other pipeline products include GTX-102, an oral mucosal spray formulation of betamethasone intended to develop neurological symptoms of A-T, including developing clinical assessments of posture and gait disturbance, and kinetic speech and oculomotor functions. GTX-101 is a topical bio-adhesive film-forming spray of bupivacaine for the treatment of PHN.
Acasti Pharma, Inc. is a biopharmaceutical company, which engages in the development and commercialization of pharmaceutical applications of its licensed rights for cardiovascular diseases. The firm is targeting three underserved orphan diseases: Subarachnoid Hemorrhage (SAH), Ataxia Telangiectasia (A-T), and Postherpetic Neuralgia (PHN). The firm's lead product candidate includes GTX-104, which is a clinical-stage nanoparticle formulation of nimodipine being developed for IV infusion in SAH patients. The firm's other pipeline products include GTX-102, an oral mucosal spray formulation of betamethasone intended to develop neurological symptoms of A-T, including developing clinical assessments of posture and gait disturbance, and kinetic speech and oculomotor functions. GTX-101 is a topical bio-adhesive film-forming spray of bupivacaine for the treatment of PHN.
This earnings call has not been analyzed yet.
If you’d like us to analyze this earnings call, click the "Request Earnings Call Analysis" button below.
